跳至主要内容
临床试验/NCT00661817
NCT00661817已完成不适用

Integrated Weight Loss Technologies for Weight and Blood Pressure Control in Urban Clinics

Washington University School of Medicine1 个研究点 分布在 1 个国家目标入组 365 人开始时间: 2006年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
365
试验地点
1
主要终点
Change in body mass index (BMI)

研究概览

简要总结

Obesity is a serious health problem that is a contributing factor for heart disease and high blood pressure. This study will evaluate a lifestyle modification program that aims to encourage weight loss and improve the health of people with high blood pressure from low income and minority communities.

详细描述

Obesity is a serious health problem in the United States, particularly among lower income and racial and ethnic minority populations. These populations have a high risk of developing heart disease and high blood pressure, and obesity is likely a contributing factor for both conditions. African-Americans, in particular, experience an earlier onset of high blood pressure and suffer more severe health consequences as a result, than do other racial and ethnic groups. This study will evaluate the effectiveness of a lifestyle modification program that will focus on reducing blood pressure levels and encouraging weight loss among patients at community health centers that serve a primarily low-income, ethnically diverse population. Researchers will also evaluate the cost effectiveness of the lifestyle modification program.

This 2-year study will enroll people who have high blood pressure. Participants will attend a baseline study visit to complete health questionnaires. They will then be randomly assigned to either receive usual care along with printed materials about maintaining a healthy weight or take part in the lifestyle modification program that incorporates health information technologies. Participants assigned to the program will visit the BFBW study Web site several times a week to review educational and motivational information. They may receive automated weekly phone calls that will prompt them to answer questions and assist them in setting goals for losing weight and managing their blood pressure. A study researcher will call participants every 6 weeks to discuss any problems and to invite participants to take part in optional walking groups or other group activities. Participants will attend group support sessions every other month and will wear a pedometer to track their walking habits. For all participants, study visits will occur at baseline and Months 6, 12, 18, and 24. All visits will include weight and blood pressure measurements, health questionnaires, and physician referrals if needed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •High blood pressure that is being treated with medication
  • •BMI between 30 and 50 kg/m2
  • •Weighs no more than 400 lbs
  • •Willing to change diet, physical activity levels, and weight
  • •Willing to be assigned to either study group
  • •Patient of a participating community health center with a record of at least one medical visit in the 12 months before study entry
  • •Primary care provider approval is needed for people with the following conditions: diabetes mellitus, a prior cardiovascular event more than 6 months before study entry, known stable cardiovascular or peripheral vascular disease

排除标准

  • •Experienced a heart attack, stroke, or an atherosclerotic cardiovascular disease (ASCVD) procedure in the 6 months before study entry
  • •Serious medical condition that is likely to interfere with an accurate measurement of weight, for which weight loss is not medically advisable, or that would cause weight loss (e.g., end-stage renal disease [ESRD] and on dialysis; diagnosis or treatment for cancer in the 2 years before study entry, other than non-melanoma skin cancer)
  • •Prior or planned bariatric surgery
  • •Use of FDA-approved prescription weight loss medication, including off label drugs (e.g., topiramate, bupropion, byetta) or over-the-counter orlistat in the 6 months before study entry
  • •Long-term use (i.e., in the 6 months before study entry) of medications likely to cause weight gain or prevent weight loss (e.g., corticosteroids, lithium, olanzapine, risperidone, clozapine)
  • •Pregnant or breastfeeding in the 6 months before study entry
  • •Plans to become pregnant in the 2 years after study entry
  • •Plans to relocate from the area in the 2 years after study entry
  • •Another member of household is a study participant or study staff member
  • •Principal investigator decides that the individual is not suitable for the study

研究组 & 干预措施

1

Active Comparator

Participants in this group will receive usual medical care and reading materials on weight loss.

干预措施: Usual Care and Reading Materials (Behavioral)

2

Experimental

Participants in this group will take part in the lifestyle modification program.

干预措施: Lifestyle Modification Program (Behavioral)

结局指标

主要结局

Change in body mass index (BMI)

时间窗: Measured at Year 2

次要结局

  • Reduction in blood pressure(Measured at Year 2)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Graham Colditz

Niess-Gain Professor in the School of Medicine

Washington University School of Medicine

研究点 (1)

Loading locations...

相似试验